The Food and Drug Administration's Process for Approving New Drugs: Oversight : Hearings Before the Subcommittee on Science, Research, and Technology of the Committee on Science and Technology, U.S. House of Representatives, Ninety-sixth Congress, First Session, June 19, 21, July 11, 1979
United States. Congress. House. Committee on Science and Technology. Subcommittee on Science, Research, and Technology
U.S. Government Printing Office, 1979 - Drugs - 1299 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
accept additional Administration advisory agency already American animal appear application approval process areas asked believe benefit Chairman clinical clinical trials Committee concerned conducted considered cost decision delay discussed disease drug approval drug lag effective efficacy entities epilepsy evaluation evidence example existing experience fact FDA's Food foreign give given going hearings human important improved increase indicated industry innovation institutional interest introduced KENNEDY kind less limited look major mean meeting months officials patients percent period pharmaceutical phase physicians present problem question reason regulations regulatory represent requirements responsibility risk safety SCHEUER scientific seizures side significant sodium specific sponsor statement studies submitted testimony testing therapeutic things treatment United valproic acid